Overview
SCIENTIFIC SCORE
Questionable
Based on 14 Researches
5.9
USERS' SCORE
Good
Based on 2 Reviews
8.3
Supplement Facts
Serving Size: 1 Softgel
Amount Per Serving
%DV
Vitamin D (as D3 Cholecalciferol)
125 mcg (5,000 IU)
625%
Top Medical Research Studies
8
We explored how vitamin D (VitD) levels relate to the activity of multiple sclerosis (MS) in patients about to start treatment. By measuring serum levels of a specific form of VitD in 230 untreated individuals with relapsing-remitting MS, we aimed to see if higher VitD could reduce disease activity over the subsequent two years.
Our findings revealed that lower VitD levels were linked to a greater likelihood of disease activity, specifically noting that patients with VitD levels below 20 ng/mL faced more than double the risk of experiencing such activity. Interestingly, we found that genetic factors also played a role; those with a genetic predisposition to higher VitD levels were more likely to have a delayed onset of MS and a better chance of maintaining a status known as No-Evidence of Disease Activity-3 (NEDA-3).
Through further analysis using Mendelian randomization, we confirmed that there is a causal relationship between VitD levels and disease activity in MS. This research highlights the potential benefits of monitoring and possibly supplementing VitD for patients, prompting a greater interest in lifestyle changes that could help manage the disease.
Our findings revealed that lower VitD levels were linked to a greater likelihood of disease activity, specifically noting that patients with VitD levels below 20 ng/mL faced more than double the risk of experiencing such activity. Interestingly, we found that genetic factors also played a role; those with a genetic predisposition to higher VitD levels were more likely to have a delayed onset of MS and a better chance of maintaining a status known as No-Evidence of Disease Activity-3 (NEDA-3).
Through further analysis using Mendelian randomization, we confirmed that there is a causal relationship between VitD levels and disease activity in MS. This research highlights the potential benefits of monitoring and possibly supplementing VitD for patients, prompting a greater interest in lifestyle changes that could help manage the disease.
Read More
7
We explored the connection between vitamin D, specifically 25-hydroxyvitamin D (25OHD), and its impact on Multiple Sclerosis (MS)—an autoimmune condition known for causing demyelination and neurological damage. The study utilized extensive genetic data to assess how levels of vitamin D might influence MS risk.
Through a large prospective cohort, we examined serum 25OHD levels and their correlation with MS. Our findings revealed a complex, non-linear relationship; particularly, the lowest quartile of vitamin D levels showcased a notable increase in MS risk. We identified twenty-four genetic loci shared between 25OHD levels and MS risk, shedding light on common biological pathways that may be involved.
While our analysis showed a causal effect of higher vitamin D levels potentially reducing MS risk, it’s important to note that increasing vitamin D levels excessively might not always be beneficial. We recommend that supplementation be moderated and highlighted SMARCA4 as a promising therapeutic target in this context.
In summary, this study emphasizes that vitamin D may play an influential role in managing MS, but underscores the need for a balanced approach to supplementation.
Through a large prospective cohort, we examined serum 25OHD levels and their correlation with MS. Our findings revealed a complex, non-linear relationship; particularly, the lowest quartile of vitamin D levels showcased a notable increase in MS risk. We identified twenty-four genetic loci shared between 25OHD levels and MS risk, shedding light on common biological pathways that may be involved.
While our analysis showed a causal effect of higher vitamin D levels potentially reducing MS risk, it’s important to note that increasing vitamin D levels excessively might not always be beneficial. We recommend that supplementation be moderated and highlighted SMARCA4 as a promising therapeutic target in this context.
In summary, this study emphasizes that vitamin D may play an influential role in managing MS, but underscores the need for a balanced approach to supplementation.
Read More
4
We explored the potential impact of vitamin D on oxidative stress in individuals with relapsing-remitting multiple sclerosis (RRMS). Our study compared two different doses of vitamin D: 2000 IU per day and a monthly dose of 15,960 IU.
Over a period of six months, participants in both groups showed a significant increase in vitamin D levels in their blood. However, we also noticed increases in markers that indicate oxidative stress, along with decreases in some antioxidant levels.
While there was a positive relationship between vitamin D levels and certain antioxidants, our findings suggest that the dosages studied may not be adequate to achieve a meaningful improvement in the balance between oxidative stress and antioxidant defense in RRMS patients.
Essentially, the potential benefits of vitamin D in reducing oxidative stress may not be realized with the doses tested in this study.
Over a period of six months, participants in both groups showed a significant increase in vitamin D levels in their blood. However, we also noticed increases in markers that indicate oxidative stress, along with decreases in some antioxidant levels.
While there was a positive relationship between vitamin D levels and certain antioxidants, our findings suggest that the dosages studied may not be adequate to achieve a meaningful improvement in the balance between oxidative stress and antioxidant defense in RRMS patients.
Essentially, the potential benefits of vitamin D in reducing oxidative stress may not be realized with the doses tested in this study.
Read More
Most Useful Reviews
7.5
Vitamin D findings
4 people found this helpful
I researched the link between D3 and multiple sclerosis and found a preliminary study contrasting high versus low daily doses. Those on 1000 IU of D3 experienced remarkably better outcomes, with nearly absent symptoms after a year. Although this study involved only 20 participants, it suggests that for those of us with MS, lesser doses may be more beneficial. I've now switched from 2000 IU to 1000 IU daily.
Read More
7.5
Effective for management
I suffer from multiple sclerosis and live in Ireland, where extra Vitamin D3 is essential due to limited sun exposure. I have been using this product for a long time and am very pleased with its quality. The pills are tiny and easy to swallow, with the right strength. My recent D3 levels are within range, confirming its effectiveness. I highly recommend this product and this company.
Read More
Medical Researches
SCIENTIFIC SCORE
Questionable
Based on 14 Researches
5.9
- All Researches
9
We evaluated how vitamin D affects multiple sclerosis (MS) by exploring the properties of immune cells in treatment-naive MS patients compared to healthy donors. Our research revealed that patients’ immune cells had heightened proinflammatory features, particularly related to key pathways involving the aryl hydrocarbon receptor (AhR) and NF-κB. This imbalance may contribute to the difficulties in managing MS effectively.
We discovered that dendritic cells derived from MS patients showed reduced tolerogenic capabilities. However, when we applied vitamin D3 and directly activated the AhR, we were able to restore these properties. Furthermore, combining vitamin D3 with a drug known as dimethyl fumarate (DMF) not only enhanced the tolerogenic effects but also provided a more effective treatment option in experiments on mice.
Our findings suggest that a combined therapy utilizing DMF and vitamin D3-tolerogenic dendritic cells has great potential in improving treatment for MS. However, it is worth noting that the analysis focuses on the combination therapy rather than isolating the effects of vitamin D alone.
We discovered that dendritic cells derived from MS patients showed reduced tolerogenic capabilities. However, when we applied vitamin D3 and directly activated the AhR, we were able to restore these properties. Furthermore, combining vitamin D3 with a drug known as dimethyl fumarate (DMF) not only enhanced the tolerogenic effects but also provided a more effective treatment option in experiments on mice.
Our findings suggest that a combined therapy utilizing DMF and vitamin D3-tolerogenic dendritic cells has great potential in improving treatment for MS. However, it is worth noting that the analysis focuses on the combination therapy rather than isolating the effects of vitamin D alone.
Read More
8
We explored the potential impact of Vitamin D supplementation on patients newly diagnosed with Multiple Sclerosis (MS). Our study involved 16 drug-naïve patients who were monitored over a year. We measured the levels of 25-hydroxy-vitamin D in their blood and evaluated how this vitamin affects the balance between pro-inflammatory and anti-inflammatory cytokines, which play significant roles in MS.
Our findings showed that these patients initially had low vitamin D levels and high levels of pro-inflammatory cytokines. Over the course of the study, participants who received vitamin D supplementation demonstrated a notable decrease in pro-inflammatory cytokine levels. Additionally, the ratio of pro-inflammatory to anti-inflammatory cytokines improved, suggesting that vitamin D may help shift the immune response towards a more protective profile.
Interestingly, while some patients also received immunotherapy, our data indicated that Vitamin D supplementation might independently contribute to better immune regulation. Patients with higher pro-inflammatory cytokine ratios appeared more susceptible to relapses, emphasizing the potential role of Vitamin D in managing MS symptoms.
This research supports the idea that having adequate levels of Vitamin D could be vital for those facing MS, as it may offer a protective mechanism through improving immune responses. Ultimately, vitamin D supplementation could be an essential component of a comprehensive treatment plan for MS patients.
Our findings showed that these patients initially had low vitamin D levels and high levels of pro-inflammatory cytokines. Over the course of the study, participants who received vitamin D supplementation demonstrated a notable decrease in pro-inflammatory cytokine levels. Additionally, the ratio of pro-inflammatory to anti-inflammatory cytokines improved, suggesting that vitamin D may help shift the immune response towards a more protective profile.
Interestingly, while some patients also received immunotherapy, our data indicated that Vitamin D supplementation might independently contribute to better immune regulation. Patients with higher pro-inflammatory cytokine ratios appeared more susceptible to relapses, emphasizing the potential role of Vitamin D in managing MS symptoms.
This research supports the idea that having adequate levels of Vitamin D could be vital for those facing MS, as it may offer a protective mechanism through improving immune responses. Ultimately, vitamin D supplementation could be an essential component of a comprehensive treatment plan for MS patients.
Read More
8
We investigated how glucagon-like peptide-1 agonists (GLP-1s) impact people with multiple sclerosis (MS), particularly focusing on weight loss and vitamin D levels. Our research examined individuals with MS who used GLP-1 medications over an extended period from 2006 to 2024.
The findings were promising. We observed that after initiating GLP-1 treatment, participants experienced a significant decrease in body mass index (BMI) by an average of 3.7%. Moreover, there was an increase in vitamin D levels, with an average rise of 8.1 ng/mL. However, there were no notable changes in disability status or walking speed.
Importantly, we found that patients did not experience any hospitalizations or deaths during the study period following GLP-1 usage. This suggests that GLP-1 medications are not only safe for people with MS but also effective in boosting vitamin D levels, which may play a role in managing MS symptoms.
The findings were promising. We observed that after initiating GLP-1 treatment, participants experienced a significant decrease in body mass index (BMI) by an average of 3.7%. Moreover, there was an increase in vitamin D levels, with an average rise of 8.1 ng/mL. However, there were no notable changes in disability status or walking speed.
Importantly, we found that patients did not experience any hospitalizations or deaths during the study period following GLP-1 usage. This suggests that GLP-1 medications are not only safe for people with MS but also effective in boosting vitamin D levels, which may play a role in managing MS symptoms.
Read More
8
We explored how vitamin D (VitD) levels relate to the activity of multiple sclerosis (MS) in patients about to start treatment. By measuring serum levels of a specific form of VitD in 230 untreated individuals with relapsing-remitting MS, we aimed to see if higher VitD could reduce disease activity over the subsequent two years.
Our findings revealed that lower VitD levels were linked to a greater likelihood of disease activity, specifically noting that patients with VitD levels below 20 ng/mL faced more than double the risk of experiencing such activity. Interestingly, we found that genetic factors also played a role; those with a genetic predisposition to higher VitD levels were more likely to have a delayed onset of MS and a better chance of maintaining a status known as No-Evidence of Disease Activity-3 (NEDA-3).
Through further analysis using Mendelian randomization, we confirmed that there is a causal relationship between VitD levels and disease activity in MS. This research highlights the potential benefits of monitoring and possibly supplementing VitD for patients, prompting a greater interest in lifestyle changes that could help manage the disease.
Our findings revealed that lower VitD levels were linked to a greater likelihood of disease activity, specifically noting that patients with VitD levels below 20 ng/mL faced more than double the risk of experiencing such activity. Interestingly, we found that genetic factors also played a role; those with a genetic predisposition to higher VitD levels were more likely to have a delayed onset of MS and a better chance of maintaining a status known as No-Evidence of Disease Activity-3 (NEDA-3).
Through further analysis using Mendelian randomization, we confirmed that there is a causal relationship between VitD levels and disease activity in MS. This research highlights the potential benefits of monitoring and possibly supplementing VitD for patients, prompting a greater interest in lifestyle changes that could help manage the disease.
Read More
7
We explored how vitamin D affects multiple sclerosis (MS), an autoimmune condition impacting the central nervous system. A combination of environmental factors, notably low vitamin D levels and Epstein-Barr virus (EBV) infection, are considered significant risk factors for developing MS in predisposed individuals.
Our focus led us to look at how vitamin D behaves in this context. Vitamin D is known for its protective role in the nervous system and its ability to modulate immune responses. We observed that individuals with low levels of vitamin D might face a higher risk of MS. Current research and clinical trials indicate that supplementing vitamin D can potentially reduce the severity of the disease.
Furthermore, vitamin D aids in regulating the immune system, striking a balance between pro-inflammatory and anti-inflammatory responses. The interconnectedness of EBV infection, vitamin D deficiency, and immune dysfunction highlights a complex relationship. Understanding these dynamics could be a crucial step toward uncovering new treatment strategies for MS.
Our focus led us to look at how vitamin D behaves in this context. Vitamin D is known for its protective role in the nervous system and its ability to modulate immune responses. We observed that individuals with low levels of vitamin D might face a higher risk of MS. Current research and clinical trials indicate that supplementing vitamin D can potentially reduce the severity of the disease.
Furthermore, vitamin D aids in regulating the immune system, striking a balance between pro-inflammatory and anti-inflammatory responses. The interconnectedness of EBV infection, vitamin D deficiency, and immune dysfunction highlights a complex relationship. Understanding these dynamics could be a crucial step toward uncovering new treatment strategies for MS.
Read More
User Reviews
USERS' SCORE
Good
Based on 2 Reviews
8.3
- All Reviews
- Positive Reviews
- Negative Reviews
7.5
Vitamin D findings
4 people found this helpful
I researched the link between D3 and multiple sclerosis and found a preliminary study contrasting high versus low daily doses. Those on 1000 IU of D3 experienced remarkably better outcomes, with nearly absent symptoms after a year. Although this study involved only 20 participants, it suggests that for those of us with MS, lesser doses may be more beneficial. I've now switched from 2000 IU to 1000 IU daily.
Read More
7.5
Effective for management
I suffer from multiple sclerosis and live in Ireland, where extra Vitamin D3 is essential due to limited sun exposure. I have been using this product for a long time and am very pleased with its quality. The pills are tiny and easy to swallow, with the right strength. My recent D3 levels are within range, confirming its effectiveness. I highly recommend this product and this company.
Read More
Frequently Asked Questions
No FAQs are available for this product and symptom.
References
- Al-Shammri S, Chattopadhyay A, Raghupathy R. Vitamin D supplementation mediates a shift towards anti-inflammatory cytokine response in Multiple Sclerosis. Med Princ Pract. 2025. doi:10.1159/000544106
- Rasheed A, Khan G. Epstein-Barr virus, vitamin D and the immune response: connections with consequences for multiple sclerosis. Front Immunol. 2024;15:1503808. doi:10.3389/fimmu.2024.1503808
- Lis M, Niedziela N, Adamczyk-Zostawa J, Zalejska-Fiolka J, Szczygieł J, et al. Comparative Effects of Vitamin D Supplementation on Oxidative Stress in Relapsing-Remitting Multiple Sclerosis. Curr Issues Mol Biol. 2024;46:14119. doi:10.3390/cimb46120845
- Balshi A, Leuenberger G, Dempsey J, Baber U, Sloane JA. Glucagon-like peptide-1 agonist safety and efficacy in a multiple sclerosis cohort. Mult Scler Relat Disord. 2025;93:106229. doi:10.1016/j.msard.2024.106229
- Yu XH, Lu HM, Li J, Su MZ, Li XM, et al. Association between 25(OH) vitamin D and multiple sclerosis: cohort, shared genetics, and Causality. Nutr J. 2024;23:151. doi:10.1186/s12937-024-01059-4
- France-Ratcliffe M, Harrison SL, Verma LA, Abdul-Rahim AH, McCallum L, et al. Vitamin D and cardiovascular outcomes in multiple sclerosis. Mult Scler Relat Disord. 2024;92:106155. doi:10.1016/j.msard.2024.106155
- Niedziela N, Nowak-Kiczmer M, Malciene L, Stasiołek M, Niedziela JT, et al. Serum Vitamin D3 as a Potential Biomarker for Neuronal Damage in Smoldering Multiple Sclerosis. Int J Mol Sci. 2024;25. doi:10.3390/ijms251910502
- Gill A, Orji C, Reghefaoui M, Peresuodei TS, Thota P, et al. The Effectiveness of Vitamin D Intake in Improving Symptoms and Relapses of Multiple Sclerosis: A Systematic Review. Cureus. 2024;16:e68565. doi:10.7759/cureus.68565
- Fondelli F, Willemyns J, Domenech-Garcia R, Mansilla MJ, Godoy-Tena G, et al. Targeting aryl hydrocarbon receptor functionally restores tolerogenic dendritic cells derived from patients with multiple sclerosis. J Clin Invest. 2024;134. doi:10.1172/JCI178949
- Alelyani M, Gameraddin M, Alshahrani R, Alaslami W, Sarhan R, et al. Assessment of vitamin D status and associated risk factors in high-altitude populations affected by multiple sclerosis: A case-control study. Medicine (Baltimore). 2024;103:e38369. doi:10.1097/MD.0000000000038369
- Balasooriya NN, Elliott TM, Neale RE, Vasquez P, Comans T, et al. The association between vitamin D deficiency and multiple sclerosis: an updated systematic review and meta-analysis. Mult Scler Relat Disord. 2024;90:105804. doi:10.1016/j.msard.2024.105804
- Lis M, Niedziela N, Adamczyk-Zostawa J, Zalejska-Fiolka J, Błachut M, et al. Can Vitamin D Reduce Inflammation? The Influence of Supplementation on Selected Immunological Markers. Int J Mol Sci. 2024;25. doi:10.3390/ijms25147592
- Lis M, Niedziela N, Adamczyk-Zostawa J, Wierzbicki K, Czuba Z, et al. Can Vitamin D Supplementation Improve Inflammation in Relapsing-Remitting Multiple Sclerosis Patients?. Biomedicines. 2024;12. doi:10.3390/biomedicines12071580
- Giordano A, Clarelli F, Pignolet B, Mascia E, Sorosina M, et al. Vitamin D affects the risk of disease activity in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2025;96:170. doi:10.1136/jnnp-2024-334062
